Outcomes

The evidence for BAM15 outcomes is limited to preclinical studies, with no published results from human clinical trials available in the provided literature. The single completed Phase 2 clinical trial (NCT04634409) for COVID-19 has no reported outcomes data.

Preclinical Outcomes

Reproductive Health Applications:

In human sperm cryopreservation studies, BAM15 demonstrated protective effects against freeze-thaw damage by stabilizing mitochondrial homeostasis, though specific quantitative measures are not detailed in the available abstracts
For oocyte quality in obesity models, BAM15 showed improvement through PPARγ-dependent mitochondrial function enhancement, but numerical outcomes are not specified

Metabolic and Energy Effects:

BAM15 functioned as a mitochondrial uncoupler in obesity treatment applications when delivered via microneedle patch systems
In metastatic breast cancer models, mitochondrial uncoupling (mechanism of BAM15) was associated with inhibition of serine catabolism through FTO activation
Energy metabolism disruption was observed in mollusk studies, accompanied by oxidative stress induction and tissue damage

Cellular Protection:

Studies suggest BAM15 may help prevent endothelial injury in hyperglycemic conditions through mitochondrial function regulation
Structure-activity relationship studies identified BAM15 as part of a class of mitochondrial protonophores, though specific potency or efficacy measures are not provided

Evidence Limitations

The strength of evidence is weak, consisting entirely of preclinical studies with limited quantitative outcome data available in the abstracts. No human efficacy or safety data from controlled trials have been published. The completed clinical trial for COVID-19 applications has not reported results, and it's unclear whether BAM15 was the primary intervention studied.

This information is for research purposes only and does not constitute medical advice. Consult healthcare professionals for medical decisions.

BAM15

Member access required